Pfizer keeps COVID sales forecast unchanged as pandemic curbs ease

Pfizer Inc maintained sales forecasts for its COVID products on Tuesday after a series of hikes to the sales outlook for its COVID-19 vaccine last year, in a sign that dizzying growth has slowed.

Several countries across the globe have eased pandemic-linked restrictions and relaxed rules related to masking and quarantines, even as cases rise in some regions.

Diminished concern over COVID among both patients and governments could generate uncertainty over Pfizer’s ability to exceed sales forecasts for its vaccine and pill, Citi analyst Andrew Baum said in a research note.

The company said it expects $22 billion in sales of its COVID pill Paxlovid this year, compared with analysts’ average expectation of $26.1 billion.

Pfizer had previously said its forecast for $22 billion in Paxlovid sales only represents a fraction of the 120 million courses the company is able to manufacture this year.

The company’s reluctance to lift that forecast could suggest a dearth of new sales contracts for the pill during the first quarter.

via Reuters

Discover more from The Dispatch

Subscribe now to keep reading and get access to the full archive.

Continue reading

Verified by MonsterInsights